Abstract
[...]we report a Chinese male patient with a history of 6q24-related TNDM (hypomethylation of the maternal allele) who relapsed at 14 years old and was successfully treated with a low dose of glimepiride. Whole exome sequencing revealed no mutations. [...]the patient was treated with Lantus (8 U/day) together with lifestyle modifications. [2] Given that patients with 6q24-related TNDM have relatively healthy beta cell function at remission, sulfonylurea treatment has a biological rationale in patients with 6q24-related TNDM, as its potential mechanisms are: (1) patients with 6q24-related TNDM presumably have intact sulfonylurea receptors at the pancreatic ß-cell and (2) the beta cells of patients with 6q24-related TNDM have decreased sensitivity to glucose, so sulfonylurea helps to improve the release of insulin.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer